Diarrhea News and Research

Latest Diarrhea News and Research

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

Taking oral contraceptives continuously, rather than as traditionally prescribed for each cycle, provides earlier relief for moderate to severe menstrual cramps -- dysmenorrhea -- according to researchers at Penn State College of Medicine.

16 Aug 2012

FDA extends PDUFA target action date for review of Santarus' UCERIS NDA

Santarus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the review of the New Drug Application (NDA) for UCERIS (budesonide) tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis from October 16, 2012 to January 16, 2013.

14 Aug 2012

‘Low’ toxicity for phase I cancer trials

Advanced cancer patients participating in phase I clinical trials at the University of Texas MD Anderson Cancer Center experienced a low rate of toxicity, researchers say.

13 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

8 Aug 2012

Communal violence in India forces up to 400,000 into overcrowded camps without sufficient food, water, medicine

"Hundreds of thousands of people sheltering in squalid, overcrowded camps in India's northeast desperately need food, water and medicines after fleeing some of the worst communal violence in a decade, officials and aid workers said on Monday," AlertNet reports.

8 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

New York University College of Nursing's (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, LAc., the Independence Foundation Endowed Professor and Founding Director of the Division of Special Studies in Symptom Management at NYUCN has been awarded a $2.5 million four-year National Institutes of Health (NIH) grant for the study of "Symptom management for irritable bowel syndrome (IBS) constipation".

7 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Public Health Wales uses Luminex's xTAG GPP for outbreak investigations during Olympic events

Luminex Corporation announced today that Public Health Wales is using Luminex's CE marked xTAG Gastrointestinal Pathogen Panel (GPP) for outbreak investigation activities during Olympic and Paralympic training and events taking place in Wales. Results of a substantial diagnostic validation of the GPP test conducted by The Public Health Wales Microbiology laboratory team at the University Hospital of Wales, Cardiff, are anticipated to be published in a peer reviewed journal

From Luminex 6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

'Fight' between bacteria in the intestines linked to chronic disease

Results from a study conducted at Georgia State University suggest that a "fight" between bacteria normally living in the intestines and the immune system, kicked off by another type of bacteria, may be linked to two types of chronic disease.

3 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Diarrhea News and Research

Latest Diarrhea News and Research

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

FDA extends PDUFA target action date for review of Santarus' UCERIS NDA

‘Low’ toxicity for phase I cancer trials

FDA extends PDUFA action date for NPS Gattex NDA

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

FDA approved drug to treat Ph- acute lymphoblastic leukemia

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

Communal violence in India forces up to 400,000 into overcrowded camps without sufficient food, water, medicine

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

Public Health Wales uses Luminex's xTAG GPP for outbreak investigations during Olympic events

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

'Fight' between bacteria in the intestines linked to chronic disease

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in